Cheng Chen
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 10%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
-
- Tuberculosis Research and Epidemiology 14
- COVID-19 Clinical Research Studies 10
- Epidemiology 27
- Mycobacterium research and diagnosis 8
- Respiratory viral infections research 6
- Co-authors
- Xueguang Zhang (5 shared papers)Jian‐An Huang (4 shared papers)Chuanyong Mu (3 shared papers)Ying Chen (1 shared paper)Qiu‐Xia Qu (10 shared papers)Yu Shen (3 shared papers)Yibei Zhu (3 shared papers)Guilin Ma (3 shared papers)
- Journals
- Oncotarget (3 papers)Therapeutic Advances in Respiratory Disease (3 papers)Respiratory Research (2 papers)BMC Cancer (2 papers)Immunology Letters (2 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Cheng Chen
89 papers receiving 1.5k citations
Cheng Chen's Hit Papers
Peers
Comparison fields: 5 of 125
- Oncology 730
- Immunology 421
- Infectious Diseases 316
- Pulmonary and Respiratory Medicine 314
- Neurology 121
Countries citing papers authored by Cheng Chen
This map shows the geographic impact of Cheng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng Chen more than expected).
Fields of papers citing papers by Cheng Chen
This network shows the impact of papers produced by Cheng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng Chen. The network helps show where Cheng Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Cheng Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 98 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Hit paper breakdown → | 2010 | 503 |
| 2 | 2012 | 88 | |
| 3 | 2020 | 83 | |
| 4 | 2011 | 76 | |
| 5 | 2012 | 64 | |
| 6 | 2020 | 64 | |
| 7 | 2009 | 56 | |
| 8 | 2015 | 46 | |
| 9 | 2020 | 37 | |
| 10 | 2015 | 37 | |
| 11 | 2017 | 32 | |
| 12 | 2008 | 30 | |
| 13 | 2020 | 24 | |
| 14 | 2019 | 23 | |
| 15 | 2011 | 23 | |
| 16 | 2013 | 19 | |
| 17 | 2023 | 17 | |
| 18 | 2021 | 15 | |
| 19 | 2013 | 14 | |
| 20 | 2019 | 14 |
About Cheng Chen
Cheng Chen is a scholar working on Infectious Diseases, Epidemiology, Pulmonary and Respiratory Medicine, Surgery and Oncology, having authored 98 papers that have together received 1.6k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (14 papers), Cancer Immunotherapy and Biomarkers (10 papers), COVID-19 Clinical Research Studies (10 papers), Immunotherapy and Immune Responses (8 papers), Mycobacterium research and diagnosis (8 papers), Diagnosis and treatment of tuberculosis (6 papers), Respiratory viral infections research (6 papers) and Lung Cancer Diagnosis and Treatment (6 papers). The work is most often cited by research in Oncology (730 citations), Immunology (421 citations), Infectious Diseases (316 citations), Pulmonary and Respiratory Medicine (314 citations) and Neurology (121 citations). Cheng Chen has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Xueguang Zhang, Jian‐An Huang, Chuanyong Mu, Ying Chen, Qiu‐Xia Qu, Yu Shen, Yibei Zhu, Guilin Ma, Linkun Hu and Xuqin Chen. Their work appears in journals such as Oncotarget, Therapeutic Advances in Respiratory Disease, Respiratory Research, BMC Cancer and Immunology Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.